Hoe verhoudt ETNB's PB Ratio zich tot zijn concurrenten?

ETNB is good value based on its Price-To-Book Ratio (1.9x) compared to the peer average (3.1x).

Hoe verhoudt ETNB's PB Ratio zich tot andere bedrijven in de US Biotechs industrie?

ETNB is expensive based on its Price-To-Book Ratio (1.9x) compared to the US Biotechs industry average (1.8x).

Wat is ETNB's PB Ratio vergeleken met zijn Fair PB Ratio? Dit is de verwachte PB Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

Insufficient data to calculate ETNB's Price-To-Book Fair Ratio for valuation analysis.

Wat is de reële prijs van ETNB als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Insufficient data to calculate ETNB's fair value for valuation analysis.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

89bio (Nasdaq:ETNB) - Aandelenkoers, Nieuws & Analyse

ETNB Overzicht aandelen

89bio, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van therapieën voor de behandeling van lever- en cardio-metabole ziekten.

Over het bedrijf

ETNB fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Revenue is forecast to grow 81.76% per year

Risicoanalyse

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

89bio, Inc. Concurrenten

Silence Therapeutics

NasdaqGM:SLN

US$827.4m

Dianthus Therapeutics

NasdaqCM:DNTH

US$822.6m

Perspective Therapeutics

NYSEAM:CATX

US$815.2m

Replimune Group

NasdaqGS:REPL

US$813.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor 89bio
Historische aandelenkoersen
Huidige aandelenkoers	US$9.14
52 Week Hoogtepunt	US$16.63
52 Week Laag	US$6.88
Bèta	0.99
11 maand verandering	27.12%
3 maanden verandering	15.11%
1 Jaar Verandering	10.25%
33 jaar verandering	-48.97%
5 jaar verandering	-56.06%
Verandering sinds IPO	-56.06%

Recent nieuws en updates

Recent updates

89bio: Surviving A Competitive Space - For Now

Oct 29

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

Sep 26

89bio: Bullish In Light Of Further MOA Being Established By Peer

Aug 07

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

May 23

89bio Still Has A Chance As NASH Race Heats Up

Oct 06

89bio completes enrollment in phase 2 trial for NASH treatment

Aug 18

89Bio rallies on Deep Track Capital disclosing 10% stake

Jul 07

89bio: Undervalued Contender In Race For First NASH Drug Approval

Jul 20

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

May 07

89bio: NASH Drug Developer With Differentiated Profile

Jan 29

We're Hopeful That 89bio (NASDAQ:ETNB) Will Use Its Cash Wisely

Jan 22

89bio expects to initiate Phase 2b NASH trial in 1H21

Jan 05

Rendement voor aandeelhouders

	ETNB	US Biotechs	US Markt
7D	14.0%	-0.7%	-1.6%
1Y	10.3%	19.8%	30.8%

Rendement versus industrie: ETNB underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: ETNB underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is ETNB's price volatile compared to industry and market?
ETNB volatility
ETNB Average Weekly Movement	8.6%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Stabiele aandelenkoers: ETNB has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: ETNB's weekly volatility (9%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2018	70	Rohan Palekar	www.89bio.com

89bio, Inc., een biofarmaceutisch bedrijf in een klinische fase, richt zich op de ontwikkeling en commercialisering van therapieën voor de behandeling van lever- en cardio-metabole ziekten. Haar belangrijkste productkandidaat is pegozafermin, een geglycoPEGyleerd analoog van fibroblastgroeifactor 21 voor de behandeling van niet-alcoholische steatohepatitis; en voor de behandeling van ernstige hypertriglyceridemie. Het bedrijf werd opgericht in 2018 en heeft zijn hoofdkantoor in San Francisco, Californië.

89bio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van 89bio zich tot de beurswaarde?
ETNB fundamentele statistieken
Marktkapitalisatie	US$968.02m
Inkomsten(TTM)	-US$174.61m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-5.5x

Koers/Winstverhouding

Is ETNB overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ETNB resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$174.61m
Inkomsten	-US$174.61m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.65
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	4.9%

Hoe presteerde ETNB op de lange termijn?

Bekijk historische prestaties en vergelijking

ETNB Overzicht aandelen

Beloningen

Risicoanalyse

89bio, Inc. Concurrenten

NasdaqGM:SLN

US$827.4m

NasdaqCM:DNTH

US$822.6m

NYSEAM:CATX

US$815.2m

NasdaqGS:REPL

US$813.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

89bio: Surviving A Competitive Space - For Now

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

Recent updates

89bio: Surviving A Competitive Space - For Now

Health Check: How Prudently Does 89bio (NASDAQ:ETNB) Use Debt?

89bio, Inc. Appoints Teresa Perney as Chief Regulatory and Quality Officer

89bio: Bullish In Light Of Further MOA Being Established By Peer

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

89bio: Pegozafermin Could Be A Game-Changer For Liver Disease - Strong Buy

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Patients with Compensated Cirrhosis

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock

Independent Director Anat Naschitz has left the company